However, targeted therapies have been approved for use in the advanced stage, recurrent, and/or metastatic HNSCC, including anti-epidermal growth factor receptor (EGFR) (cetuximab) and anti-programmed cell death protein (PD-1) therapy (pembrolizumab) [3,4,5]. Here, EGFR is linked to head and neck squamous cell carcinoma.